{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:23:00Z","timestamp":1759191780201,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jhep.2021.04.057","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T14:50:40Z","timestamp":1621608640000},"page":"820-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Linkage of resistance-associated substitutions in GT1 sofosbuvir\u00a0+ NS5A inhibitor failures treated with glecaprevir\/pibrentasvir"],"prefix":"10.1016","volume":"75","author":[{"given":"Gary P.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretja L.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-6886","authenticated-orcid":false,"given":"Jens J.","family":"Kort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-0481","authenticated-orcid":false,"given":"Gurjit S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layla","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh L.","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry C.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-7547","authenticated-orcid":false,"given":"Ken","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Magee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-3831","authenticated-orcid":false,"given":"Chandni B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan A.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy A.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.04.057_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.04.057_bib2","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical practice. Chronic hepatitis C infection","volume":"364","author":"Rosen","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.057_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s40471-017-0108-x","article-title":"Hepatitis C: Review of the epidemiology, clinical care, and continued challenges in the direct acting antiviral era","volume":"4","author":"Millman","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jhep.2021.04.057_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","article-title":"Global control of hepatitis C: where challenge meets opportunity","volume":"19","author":"Thomas","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib9","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.04.057_bib10","article-title":"Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.04.057_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2021.04.057_bib12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jvh.12932","article-title":"Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures","volume":"25","author":"Jeong","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.04.057_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In\u00a0Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.04.057_bib14","article-title":"In\u00a0Vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2021.04.057_bib15","unstructured":"Abbvie Inc. Mavyret (glecaprevir and pibrentasvir). Package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s008lbl.pdf 2019."},{"key":"10.1016\/j.jhep.2021.04.057_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.04.057_bib17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.04.057_bib18","unstructured":"AASLD-IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. https:\/\/www.hcvguidelines.org. accessed May 11,\u00a02020."},{"key":"10.1016\/j.jhep.2021.04.057_bib19","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.04.057_bib20","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41598-018-21303-2","article-title":"Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir\/sofosbuvir or simeprevir\/sofosbuvir against GT1 HCV infection","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2021.04.057_bib21","doi-asserted-by":"crossref","first-page":"14421","DOI":"10.1038\/s41598-017-15007-2","article-title":"Sofosbuvir (SOF) suppresses ledipasvir (LDV)-resistant mutants during SOF\/LDV combination therapy against genotype 1b hepatitis C virus (HCV)","volume":"7","author":"Brown","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2021.04.057_bib22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/QAD.0000000000000997","article-title":"CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3","volume":"30","author":"Liu","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.jhep.2021.04.057_bib23","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/nar\/gkh340","article-title":"MUSCLE: multiple sequence alignment with high accuracy and high throughput","volume":"32","author":"Edgar","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2021.04.057_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/molbev\/msu300","article-title":"IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies","volume":"32","author":"Nguyen","year":"2015","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.jhep.2021.04.057_bib25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jhep.2018.07.023","article-title":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients","volume":"69","author":"Sarrazin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.04.057_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.04.057_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.04.057_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3851\/IMP3253","article-title":"Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection","volume":"23","author":"Lahser","year":"2018","journal-title":"Antivir Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821003391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821003391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:28Z","timestamp":1759174948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821003391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0168827821003391"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.04.057","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linkage of resistance-associated substitutions in GT1 sofosbuvir\u00a0+ NS5A inhibitor failures treated with glecaprevir\/pibrentasvir","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.04.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}